Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Brisson

Showing results (161-170 of 171) with videos related to

Pageof 18
Sort By:
Radiation Oncology Journal|July 5, 2023
Nationwide changes in radiation oncology travel and location of care before and during the COVID-19 pandemicAlexandra N De Leo, Fantine Giap, Matthew M Culbert, et al.
Cancer|May 5, 2020
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO studyTanguy Y Seiwert, Sara Kochanny, Kevin Wood, et al.
International Journal of Radiation Oncology, Biology, Physics|April 21, 2020
Dose and Volume De-Escalation for Human Papillomavirus-Positive Oropharyngeal Cancer is Associated with Favorable Posttreatment Functional OutcomesCorey C Foster, Tanguy Y Seiwert, Ellen MacCracken, et al.
Cancer|February 20, 2020
A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinomaSara E Kochanny, Francis P Worden, Douglas R Adkins, et al.
Environmental Science & Technology|April 16, 2008
Extraction and optical fluorescence method for the measurement of trace beryllium in soilsAnoop Agrawal, John P Cronin, Akshay Agrawal, et al.
Oral Oncology|May 1, 2018
Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experienceCorey C Foster, James M Melotek, Ryan J Brisson, et al.
Infection and Immunity|September 25, 1999
Conservation and accessibility of an inner core lipopolysaccharide epitope of Neisseria meningitidisJ S Plested, K Makepeace, M P Jennings, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 28, 2018
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancerT Y Seiwert, C C Foster, E A Blair, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 7, 2019
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancerT Y Seiwert, C C Foster, E A Blair, et al.
International Journal of Radiation Oncology, Biology, Physics|August 12, 2016
Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck CancerTanguy Y Seiwert, James M Melotek, Elizabeth A Blair, et al.
Pageof 18

Showing results (161-170 of 171) with videos related to

Sort By:
Pageof 18
Radiation Oncology Journal|July 5, 2023
Nationwide changes in radiation oncology travel and location of care before and during the COVID-19 pandemicAlexandra N De Leo, Fantine Giap, Matthew M Culbert, et al.
Cancer|May 5, 2020
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO studyTanguy Y Seiwert, Sara Kochanny, Kevin Wood, et al.
International Journal of Radiation Oncology, Biology, Physics|April 21, 2020
Dose and Volume De-Escalation for Human Papillomavirus-Positive Oropharyngeal Cancer is Associated with Favorable Posttreatment Functional OutcomesCorey C Foster, Tanguy Y Seiwert, Ellen MacCracken, et al.
Cancer|February 20, 2020
A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinomaSara E Kochanny, Francis P Worden, Douglas R Adkins, et al.
Environmental Science & Technology|April 16, 2008
Extraction and optical fluorescence method for the measurement of trace beryllium in soilsAnoop Agrawal, John P Cronin, Akshay Agrawal, et al.
Oral Oncology|May 1, 2018
Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experienceCorey C Foster, James M Melotek, Ryan J Brisson, et al.
Infection and Immunity|September 25, 1999
Conservation and accessibility of an inner core lipopolysaccharide epitope of Neisseria meningitidisJ S Plested, K Makepeace, M P Jennings, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 28, 2018
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancerT Y Seiwert, C C Foster, E A Blair, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 7, 2019
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancerT Y Seiwert, C C Foster, E A Blair, et al.
International Journal of Radiation Oncology, Biology, Physics|August 12, 2016
Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck CancerTanguy Y Seiwert, James M Melotek, Elizabeth A Blair, et al.
Pageof 18